Seoul: South Korean scientists have discovered that people who use gliptin, a type 2 diabetes drug, also have a decrease in substances related to mental illness.
This means that the drug can treat diabetes as well as protect the brain.
This research is still in its infancy, showing that the common diabetes drug “DPP4I” (also known as “gliptin”) additionally reduces certain substances (biomarkers) that Mental illness is one of the most important symptoms of Alzheimer’s.
The study was conducted on 282 volunteers for six years, of whom 141 did not have diabetes and the remaining 141 had diabetes.
This second group of 141 volunteers also included 70 people who were taking gliptin during diabetes, while 71 people were using other medications to control their diabetes.
The average age of all of them was 76 years old, and they all had early signs of Alzheimer’s disease.
According to a report published in the latest issue of the research journal “Neurology”, at the end of the six-year study, it was found that the progression of Alzheimer’s in volunteers who took gliptin was significantly higher than in those who did not use the drug. Was low
After psychiatric tests and careful medical examination of the volunteers, the experts found that the volunteers who used gliptin not only had better learning abilities but also had significantly lower biomarkers with increasing levels in the brain, leading to Alzheimer’s disease. Gives the address of
However, researchers do not yet know how gliptin benefits the brain and hinders the progression of Alzheimer’s.
To better test the effects of glyptin on brain protection, they are now developing a comprehensive research plan that will also use glyptin in people who do not have diabetes but have early signs of Alzheimer’s.
However, the investigation could only begin with the approval of the South Korean government.